Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798029 · ClinicalTrials.gov registry record · Phase 2
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02798029: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02798029 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02798029, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions while sparing normal tissues.
Interventions
- RADIATION Frameless Fractionated Stereotactic Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-08-08 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798029
The ClinicalTrials.gov registry entry for NCT02798029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Frameless Fractionated Stereotactic Radiation Therapy is the first listed.
NCT02798029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02798029 about?
NCT02798029 is a clinical study titled "Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases". This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases. Frameless fractionated stereotactic radiosurgery is a specialized radiation therapy that delivers 3 to 5, high dose fractions of radiation directly to the brain lesions ...
What is the current status of trial NCT02798029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-08-08. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT02798029?
The interventions under investigation include: Frameless Fractionated Stereotactic Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02798029?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.